|
|
|
Weekly Market: Markets end week with modest losses
|
|
Friday, August 14, 2015 |
| | | Market Commentary | | | Markets end week with modest losses | | The Indian markets wrapped up the week ended August 14, 2015 in the red zone. The Sensex ended 0.60% lower, while the Nifty fell 0.54% in the week. | |
 Major Headlines for the week:
Indian indices:
Welcome to the 'Weekly Market Wrap' for August 14, 2015. Indian markets ended lower for the week ended August 14, 2015. After trading lower in first three trading days of the week following a surprise devaluation of the yuan by China, stocks recovered on penultimate day before rallying on last trading day of the week on hopes of interest rate cut by the Reserve Bank of India (RBI) as wholesale price index as the annual rate of inflation contracted to a decade low in July. The barometer index, the S&P BSE Sensex regained the psychological 28,000 mark after diving below that level during the week.
The S&P BSE Mid-Cap index fell 103.74 points or 0.9% to settle at 11,453.78. The S&P BSE Small-Cap index declined 337.69 points or 2.79% to settle at 11,766.78.
The 30-share S&P BSE Sensex declined 169.08 points or 0.6% to settle at 28,067.31. The 50-unit CNX Nifty fell 46.05 points or 0.54% to settle at 8,518.55.
Weekly market trend from August 10, 2015 - August 14, 2015:
August 10- Indian shares gave up early gains on Monday and ended nearly half a percent lower, marking their biggest single-day loss in two weeks, after a government official fanned doubts that the goods and service tax (GST) bill was unlikely to be cleared in the current session of parliament. The S&P BSE Sensex and CNX Nifty ended 0.48%-0.46% lower each. The Sensex surrendered more than 300 points from the highs of the day to end at 28,101, weaker by 135 points or 0.4% and the Nifty settled at 8,525, down 39 points.
August 11- Indian shares fell on Tuesday, marking their lowest close in nearly two weeks, led by declines in lenders after State Bank of India's quarterly results disappointed investors. The S&P BSE Sensex and CNX Nifty ended 0.84%-0.74% lower each. The 30-share Sensex end 236 points lower at 27,866 and the 50-share Nifty closed 63 points lower at 8,462.
August 12- Indian shares fell on Wednesday, hitting a two-week low, as uncertainty over the fate of a key nationwide tax bill and global volatility following devaluation of the Chinese yuan weighed on blue chips. The S&P BSE Sensex and CNX Nifty ended 1.27%-1.33% lower each. The Sensex fell 354 points or 1.3% to close at 27,512 levels and the Nifty declined 113 points or 1.3% to close below the crucial level of 8,350 at 8,349.
August 13- Indian shares snapped their four-day losing streak on Thursday as investors bought beaten down stocks while a news report that a government panel had questioned the controversial minimum alternate tax on foreign investors also helped. The S&P BSE Sensex and CNX Nifty ended 0.14%-0.08% higher each. The 30 share Sensex ended at 27,550 levels, up by 37 points while the 50-share Nifty ended at 8,356 levels, up by 6 points.
August 14- India's NSE index rose about 2 percent, heading towards its biggest single-day gain in seven months as the rupee recovered from a 23-month low, while hopes that the central bank might  cut rates in its September meeting also helped. The S&P BSE Sensex and CNX Nifty ended 1.88%-1.95% higher each. The Sensex ended at 28,067, stronger by 517 points or 1.8% and the Nifty settled at 8,519, up 162 points.
Global indices:
Majority of the Global Indices ended in red except Shanghai Composite were up 5.91%. Topmost losers were: Dax100 down 5.34%, CAC40 down 4.04%, Dow Jones down 2.80%, FTSE down 2.73% and Hang Seng down 2.29%.
 Sectoral and stock screening:
Among 13 Sectoral Indices: Top Gainer: S&P BSE IT gained 4.06%, S&P BSE HC gained 3.07% and S&P BSE TECk gained 2.41%. Top Losers: S&P BSE Metal down 9.99%, S&P BSE PSU down 4.91% and S&P BSE Oil&Gas down 2.68%.
| | Looking at the 'A' group stocks, the top three gainers of the week were: Jubilant Life Sciences up 20.37%, Glenmark Pharmaceuticals up 12.46% and Divis Laboratories up 10.77%.
Top three losers of the week were: Kaveri Seed Company down 20.40%, IL&FS Transportation Networks down 18.06% and NALCO down 17.79%.
FII/MF activity:
The foreign institutional investors (FIIs) have been the net sellers of the Indian stocks to the tune of Rs2356.34 crore as on August 12, 2015 and the domestic investors bought Indian shares worth a net of Rs753.90 crore as on August 12, 2015.
| | TOP MOVERS (GROUP A) |  | | | | | | | | Jubilant Life Sciences | 344.25 | 20.37 | | | Glenmark Pharma | 1,133.95 | 12.46 | | | Divi's Lab | 2,183.65 | 10.77 | | | | | Kaveri Seed Company | 601.80 | -20.40 | | | IL&FS Transport | 119.75 | -18.06 | | | | | | | | | FII/MF ACTIVITIES | | | | | | | Gross purchase | 10,895.31 | 2,886.80 | | | Gross sale | 13,251.65 | 2,132.90 | | | Net investment | -2,356.34 | 753.90 | | | | | | | | | Data as on August 12, 2015 | | | | Market Outlook for the coming week!
In the coming week, trend in global markets, investment by foreign portfolio investors (FPIs) and domestic institutional investors (DIIs), the movement of rupee against the dollar, crude oil price movement and the progress of monsoon rains will also dictate trend on the bourses in the near term.
Shares of public sector oil marketing companies (PSU OMCs) will be in focus as they undertake a review of fuel prices during the middle of the month. The review takes place during the middle of the month and on the last day of the month based on the average imported oil price in the preceding fortnight.
Among global events, on Wednesday, 19 August 2015, the US Federal Reserve releases minutes from its July 28-29 meeting that may shed light on the debate policy makers are having over the timing of the first increase in the nation's benchmark interest rate since 2006.
All eyes will be on Greece ahead of debt repayment deadline of 20 August 2015. The country must make a 3.2 billion-euro ($3.6 billion) payment to the European Central Bank by 20 August 2015. Greece's creditors are seeking to reach an agreement on an aid program in time for the country to make the payment. | | | | To know more about our products and services, click here. |  | REGISTRATION DETAILS Regd Add: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai - 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos. BSE - INB/INF011073351 ; BSE- CD ; NSE - INB/INF231073330 ; CD-INE231073330 ; MCX Stock Exchange - INB/INF261073333 ; CD-INE261073330 ; DP - NSDL-IN-DP-NSDL-233-2003 ; CDSL-IN-DP-CDSL-271-2004 ; PMS-INP000000662 ; Mutual Fund-ARN 20669 ; Commodity trading through Sharekhan Commodities Pvt. Ltd.: MCX-10080 ; (MCX/TCM/CORP/0425) ; NCDEX-00132 ; (NCDEX/TCM/CORP/0142) ; NCDEX SPOT-NCDEXSPOT/116/CO/11/20626 ; For any complaints email at igc@sharekhan.com ; Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and Do's & Don'ts by MCX & NCDEX and the T & C on www.sharekhan.com before investing. | | | | "This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.
The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on a reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as he deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of SHAREKHAN may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licencing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Either SHAREKHAN or its affiliates or its directors or employees/representatives/clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The analyst certifies that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. Further, no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document." Compliance Officer: Ms. Namita Amod Godbole; Tel: 022-6115000; e-mail: compliance@sharekhan.com
Contact: myaccount@sharekhan.com | | | |
|
posted by Anonymous @ 11:23 AM  |
|
|
|
|
|
